| Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: a case report. | |
| | |
MedLine Citation:
|
PMID: 20661027 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Akinetic mutism is a rare, complex neuropathologic disorder. The pharmaceutical treatment of akinetic mutism typically includes dopaminergic agents, but the resulting therapeutic effects are often unsatisfactory, and it remains unclear whether late treatment using these medications is effective. We present a case study of a 53-year-old male patient who developed akinetic mutism for a period of 7 months after a subarachnoid hemorrhage. The hemorrhage was caused by a ruptured aneurysm in the right anterior communicating artery, followed by a secondary infarction in the territory of the right anterior cerebral artery. Baseline brain F-18 fluorodeoxyglucose positron emission tomographic images revealed decreased glucose metabolism in both frontal lobes. Treatment with atomoxetine, a selective norepinephrine reuptake inhibitor, for a period of 8 weeks led to a clinically significant improvement in the patient's cognitive function and activities of daily living. A subtraction brain positron emission tomographic analysis after atomoxetine medication revealed increased cerebral glucose metabolism in both the premotor and visual association cortices. Thus, we suggest that atomoxetine can be a useful therapeutic option in the treatment of chronic akinetic mutism. |
| | |
Authors:
|
Yong Wook Kim; Ji-Cheol Shin; Young-Sil An |
Related Documents
:
|
19817507 - Medical management of adrenal disease: a narrative review. 16775017 - Expanding research on the racial disparity in medical treatment with ideas from sociology. 19480337 - An unusual presentation of gastrointestinal obstruction in a three-year-old boy. 8540297 - The biological basis of medical treatment of endometriosis. 10171397 - Bioethics and anti-bioethics in light of nazi medicine: what must we remember? 17515187 - Accuracy of injection into the basal joint of the thumb. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 33 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-27 Completed Date: 2010-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 209-11 Citation Subset: IM |
Affiliation:
|
Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. ywkim1@yuhs.ac |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Akinetic Mutism
/
drug therapy*,
metabolism,
radionuclide imaging Aneurysm, Ruptured / complications Cognition / drug effects Fluorodeoxyglucose F18 / diagnostic use, metabolism Frontal Lobe / drug effects, metabolism, radionuclide imaging* Glucose / metabolism Humans Male Middle Aged Norepinephrine Plasma Membrane Transport Proteins / antagonists & inhibitors Occipital Lobe / drug effects, metabolism, radionuclide imaging* Positron-Emission Tomography Propylamines / therapeutic use* Subarachnoid Hemorrhage / etiology Subtraction Technique Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Norepinephrine Plasma Membrane Transport Proteins; 0/Propylamines; 0/SLC6A2 protein, human; 50-99-7/Glucose; 63503-12-8/Fluorodeoxyglucose F18; 83015-26-3/atomoxetine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis fa...
Next Document: Quetiapine-induced hyperventilation and dyspnea.